Cipla Q3FY22 Preview: Revenue seen at Rs 55,434 million, PAT at Rs7,528 million

25 Jan 2022 , 11:27 AM

Result date: 25th January, 2022

Recommendation: Buy

Target price: Rs1130

(Source: IIFL Research)

Cipla’s PAT could inch up by 1% on a YoY basis to Rs7,528 million. Revenue is likely to increase by 7% YoY to Rs 55,434 million.

The company’s India business is expected to rise 6% YoY owing to the higher contribution of COVID products in the base quarter.

Important management insights to watch out for:

• USFDA approval for Advair
• Progress on other pipeline respiratory products
• USFDA clearance for the Goa plant and approval for Abraxane

Rs. Million	December 2021 estimates	YoY change
Revenue	55,434	7%
EBITDA	12,768	4%
PAT	7,528	1%

Source: Company, IIFL Research